Patent Term Extension Application for BRIUMVI® (ublituximab-xiiy), Patent No. 9,873,745 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

FDA-2023-E-3264

Patent Term Extension Application for BRIUMVI® (ublituximab-xiiy), Patent No. 9,873,745

Documents

Comments

Description

OPEN

Comment Period OpensAug 18, 2023

Comment Period ClosesAug 16, 2025

Type	Title	Posted	Comments	Status
Other	Letter from FDA CDER to U.S. Patent and Trademark Office	Apr 21, 2026	--

CDER

Patent Term Extension Application

Fish & Richardson P.C.

TG Therapeutics, Inc.

BRIUMVI (ublituximab-xiiy)

Patent No. 9,873,745

OPEN